ストックスクリーナーアプリを入手
77.09
16.71%
11.04
アフターアワーズ：
76.15
-0.94
-1.22%
前日終値:
$66.05
開ける：
$74.685
24時間の取引高:
18.09M
Relative Volume:
8.47
時価総額：
$9.58B
収益：
$88.04M
当期純損益:
$-784.96M
株価収益率:
-11.80
EPS:
-6.5335
ネットキャッシュフロー:
$-534.82M
1週間 パフォーマンス:
+27.02%
1か月 パフォーマンス:
+15.53%
6か月 パフォーマンス:
+30.24%
1年 パフォーマンス:
+110.23%
1日の値動き範囲:
$73.06
$80.20
1週間の範囲:
$58.65
$80.20
52週間の値動き範囲:
$29.31
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
77.09 | 8.21B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics stock hits 52-week high at 74.35 USD By Investing.com - Investing.com India
Cytokinetics (CYTK) Hits 52-Week High as Revenues Soar Over 1,000% - Yahoo Finance
5 Stocks Turning Heads With Double-Digit Gains - Insider Monkey
Cytokinetics Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge - Investing.com UK
Insider Sell Alert: Andrew Callos Sells Shares of Cytokinetics I - GuruFocus
Cytokinetics EVP Malik sells $270,795 in company stock By Investing.com - Investing.com Canada
Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial - Yahoo Finance
Cytokinetics Q1 2026 Earnings Call Transcript - MarketBeat
Cytokinetics EVP Malik sells $270,795 in company stock - Investing.com
Cytokinetics (CYTK) Q1 2026 Earnings Transcript - AOL.com
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Singapore
Cytokinetics Insider Sold Shares Worth $270,795, According to a Recent SEC Filing - marketscreener.com
Cytokinetics announces proposed public offering of common stock - marketscreener.com
Cytokinetics (CYTK) EVP executes 3,500-share option exercise and sale - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Cytokinetics Incoffers common stock with aggregate public offering price of $650 millionSEC filing - marketscreener.com
Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge By Investing.com - Investing.com Canada
Cytokinetics Q1 Loss Widens, Revenue Rises - marketscreener.com
Earnings Flash (CYTK) Cytokinetics Posts Q1 Loss $1.67, vs. FactSet Est of $1.65 Loss - marketscreener.com
Cytokinetics plans $650 million common stock offering - Investing.com
Cytokinetics plans $650M stock offering - MSN
Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q1 Revenue $19.4M, vs. FactSet Est of $8.5M - marketscreener.com
Cytokinetics (NASDAQ: CYTK) seeks $650M via common stock shelf offering - Stock Titan
Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline - TipRanks
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics: Q1 Earnings Snapshot - marketscreener.com
Insider to sell 23,906 Common shares — Cytokinetics (NASDAQ: CYTK) - Stock Titan
Cytokinetics plans $650 million common stock offering By Investing.com - Investing.com Canada
Cytokinetics Announces Proposed Public Offering of Common Stock - The Manila Times
Director Wierenga trims Cytokinetics (CYTK) stake via option exercise and sale - Stock Titan
How This Biotech Scored 'A Clear Win' Where Bristol Myers Failed - Investor's Business Daily
Cytokinetics (CYTK) CFO trims stake with 23,906-share sale - Stock Titan
Biotech Cytokinetics seeks $650M stock sale, plus 15% option - Stock Titan
Cytokinetics stock adds more than $1 billion of valuation in a single day — Here's why - The Business Journals
BofA raises Cytokinetics price target on ACACIA trial results By Investing.com - Investing.com Australia
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics (NASDAQ: CYTK) details MYQORZO rollout and $1.1B cash - Stock Titan
Cytokinetics (CYTK) EVP Callos exercises options and sells 11,333 shares - Stock Titan
[10-Q] CYTOKINETICS INC Quarterly Earnings Report - Stock Titan
MYQORZO launch drives revenue jump as Cytokinetics (NASDAQ: CYTK) posts Q1 2026 loss - Stock Titan
680 patients prescribed MYQORZO in Q1; EU approval follows - Stock Titan
BofA raises Cytokinetics price target on ACACIA trial results - Investing.com
Needham Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $102 - 富途牛牛
MSN Money - MSN
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics earnings on deck as trial results loom large - Investing.com
CYTK Stock Jumps As Traders Brace For ACACIA Data - StocksToTrade
Why Cytokinetics Stock Is Surging After Trial Win - TipRanks
Cytokinetics gets jump on BMS as Myqorzo succeeds in non-obstructive HCM trial - FirstWord Pharma
Cytokinetics stock hits 52-week high after ACACIA-HCM trial - Yahoo Finance
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):